Again, there were more M2-like (F4/80+/CD206+) and less M1-like (F4/80+/CD11c+) bone marrow-derived TAMs (CD45high) in Sr-a1−/− glioma, but there was no significant difference in microglia (CD45low) (M1 BMDM: Sr-a1+/+ glioma: 41.25% ± 4.68%, Sr-a1−/− glioma: 16.7% ± 2.33%; M2 BMDM: Sr-a1+/+ glioma: 36.3% ± 7.55%, Sr-a1−/− glioma: 60.88% ± 2.20%) (Figure 4F). This evidence concerns the gene SRA1 and central nervous system cancer.